{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:04:02Z","timestamp":1778713442405,"version":"3.51.4"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Progressive myoclonic epilepsy (PME) is a group of rare diseases characterized by progressive myoclonus, cognitive impairment, ataxia, and other neurologic deficits. PME has high genetic heterogeneity, and more than 40 genes are reportedly associated with this disorder. <jats:italic>SEMA6B<\/jats:italic> encodes a member of the semaphorin family and was first reported to cause PME in 2020. Herein, we present a rare case of PME due to a novel <jats:italic>SEMA6B<\/jats:italic> gene mutation in a 6-year-old boy born to healthy non-consanguineous Chinese parents. His developmental milestones were delayed, and he developed recurrent atonic seizures and myoclonic seizures without fever at 3 years and 11 months of age. He experienced recurrent myoclonic seizures, non-convulsive status epilepticus (NCSE), atonic seizures, and atypical absence seizures during the last 2 years. At different time points since onset, valproic acid, levetiracetam, piracetam, and clobazam were used to control the intractable seizures. Notably, NCSE was controlled by a combination of piracetam with clobazam and valproic acid instead of intravenous infusion of midazolam and phenobarbital. Due to the limited number of cases reported to date, the clinical description of our case provides a better understanding of the genotype\u2013phenotype correlations associated with PME and indicate that piracetam may be effective against NCSE in patients with <jats:italic>SEMA6B<\/jats:italic>-related PME.<\/jats:p>","DOI":"10.3389\/fped.2022.859183","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T09:28:43Z","timestamp":1651138123000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Non-convulsive Status Epilepticus in SEMA6B-Related Progressive Myoclonic Epilepsy: A Case Report With Literature Review"],"prefix":"10.3389","volume":"10","author":[{"given":"Jing","family":"Duan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanqi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanzhen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahui","family":"Mai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxiang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1080\/14734220410035356","article-title":"Progressive myoclonic epilepsy.","volume":"3","author":"Zupanc","year":"2004","journal-title":"Cerebellum."},{"key":"B2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40272-019-00378-y","article-title":"Drug treatment of progressive myoclonic epilepsy.","volume":"22","author":"Holmes","year":"2020","journal-title":"Pediatr Drugs."},{"key":"B3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.seizure.2019.08.012","article-title":"The best evidence for progressive myoclonic epilepsy: a pathway to precision therapy.","volume":"71","author":"Orsini","year":"2019","journal-title":"Seizure."},{"key":"B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42494-020-00023-z","article-title":"Clinical phenotype features and genetic etiologies of 38 children with progressive myoclonic epilepsy.","volume":"2","author":"Zhang","year":"2020","journal-title":"Acta Epileptol."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000641","article-title":"Progressive myoclonus epilepsies: diagnostic yield with next-generation sequencing in previously unsolved cases.","volume":"7","author":"Canafoglia","year":"2021","journal-title":"Neurol Genet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.ajhg.2021.03.013","article-title":"Progressive myoclonus epilepsies\u2014residual unsolved cases have marked genetic heterogeneity including dolichol-dependent protein glycosylation pathway genes.","volume":"108","author":"Courage","year":"2021","journal-title":"Am J Hum Genet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ajhg.2020.02.011","article-title":"De novo truncating variants in the last exon of SEMA6B cause progressive myoclonic epilepsy.","volume":"106","author":"Hamanaka","year":"2020","journal-title":"Am J Hum Genet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/acn3.51403","article-title":"Zonisamide-responsive myoclonus in SEMA6B-associated progressive myoclonic epilepsy.","volume":"8","author":"Herzog","year":"2021","journal-title":"Ann Clin Transl Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/humu.24222","article-title":"Incorporation of exome-based CNV analysis makes trio-WES a more powerful tool for clinical diagnosis in neurodevelopmental disorders: a retrospective study.","volume":"42","author":"Zhai","year":"2021","journal-title":"Hum Mutat."},{"key":"B10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology.","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1006\/geno.2001.6525","article-title":"Human semaphorin 6B [(HSA) SEMA6B], a novel human class 6 semaphorin gene: alternative splicing and all-trans-retinoic acid-dependent downregulation in glioblastoma cell lines.","volume":"73","author":"Correa","year":"2001","journal-title":"Genomics."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1242\/dev.112185","article-title":"Semaphorin 6B acts as a receptor in post-crossing commissural axon guidance.","volume":"141","author":"Andermatt","year":"2014","journal-title":"Development."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1007\/s12031-021-01880-0","article-title":"De novo SEMA6B variant in a Chinese patient with progressive myoclonic epilepsy-11 and review of the literature.","volume":"71","author":"Li","year":"2021","journal-title":"J Mol Neurosci."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.633819","article-title":"Novel truncating and missense variants in SEMA6B in patients with early-onset epilepsy.","volume":"9","author":"Xiaozhen","year":"2021","journal-title":"Front Cell Dev Biol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s12264-021-00717-5","article-title":"Frameshift variant in the SEMA6B gene causes global developmental delay and febrile seizures.","volume":"37","author":"Shu","year":"2021","journal-title":"Neurosci Bull."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.633819","article-title":"Novel truncating and missense variants in SEMA6B in patients with early-onset epilepsy.","volume":"9","author":"Xiaozhen","year":"2021","journal-title":"Front Cell Dev Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1684\/epd.2014.0654","article-title":"Seizure control in unverricht-lundborg disease: a single-centre study.","volume":"16","author":"Roivainen","year":"2014","journal-title":"Epileptic Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.yebeh.2004.11.014","article-title":"Add-on therapy with topiramate in progressive myoclonic epilepsy.","volume":"6","author":"Aykutlu","year":"2005","journal-title":"Epilepsy Behav."},{"key":"B19","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1212\/wnl.38.6.928","article-title":"Progressive myoclonus epilepsy treated with zonisamide.","volume":"38","author":"Henry","year":"1988","journal-title":"Neurology."},{"key":"B20","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.nurt.2006.11.002","article-title":"Clobazam.","volume":"4","author":"Ng","year":"2007","journal-title":"Neurotherapeutics."},{"key":"B21","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/epi.13662","article-title":"Perampanel in 12 patients with unverricht-lundborg disease.","volume":"58","author":"Crespel","year":"2017","journal-title":"Epilepsia."},{"key":"B22","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1586\/ern.12.90","article-title":"Treatment of myoclonic seizures.","volume":"12","author":"Striano","year":"2012","journal-title":"Expert Rev Neurother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/s0387-7604(99)00113-8","article-title":"When antiepileptic drugs aggravate epilepsy.","volume":"22","author":"Genton","year":"2000","journal-title":"Brain Dev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1528-1167.2008.01546.x","article-title":"Clinical picture of EPM1-unverricht-lundborg disease.","volume":"49","author":"K\u00e4lvi\u00e4inen","year":"2008","journal-title":"Epilepsia."},{"key":"B25","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/dmcn.12634","article-title":"Standardized assessment of seizures in patients with juvenile neuronal ceroid lipofuscinosis.","volume":"57","author":"Augustine","year":"2015","journal-title":"Dev Med Child Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1055\/s-0036-1579784","article-title":"Considering valproate as a risk factor for rapid exacerbation of complex movement disorder in progressed stages of late-infantile CLN2 disease.","volume":"47","author":"Johannsen","year":"2016","journal-title":"Neuropediatrics."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.859183\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T09:28:50Z","timestamp":1651138130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.859183\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":26,"alternative-id":["10.3389\/fped.2022.859183"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.859183","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"article-number":"859183"}}